Identification of genetic contribution to ischemic stroke by screening of single nucleotide polymorphisms in stroke patients by using a case control study design by unknown
Kumar et al. BMC Neurology 2013, 13:136
http://www.biomedcentral.com/1471-2377/13/136STUDY PROTOCOL Open AccessIdentification of genetic contribution to ischemic
stroke by screening of single nucleotide
polymorphisms in stroke patients by using a case
control study design
Amit Kumar1, Ram Sagar1, Pradeep Kumar1, Jitendra K Sahu2, Ashoo Grover3, Achal K Srivastava1,
S Vivekanandhan4 and Kameshwar Prasad1*Abstract
Background: Stroke is the second most common cause of death and disability worldwide. It is a multi-factorial
disease influenced by both environmental and genetic factors. Studies from the different ethnic regions of world
have reported variable results on association of Apolioprotein E (APOE), Methylenetetrahydrofolate reductase
(MTHFR), Endothelial Nitric Oxide Synthase (ENOS), Factor V Leiden (F5), Cytochrome P450 4F2 (CYP4F2), beta-
fibrinogen and Phosphodiesterase 4D (PDE4D) gene in stroke. There has been substantial evidence from the
European descent genetic studies showing that genetic risk of stroke varies as per specific subtypes of ischemic
stroke.
This study aims to test the hypothesis that above mentioned encoding gene polymorphisms are associated with
stroke and to determine whether risk varies as per specific subtypes of stroke.
Methods/Design: The study design would be case–control study. Six hundred cases with diagnosis of stroke and 600
age and sex matched controls will be recruited. Controls will be matched in 1:1 ratio. Baseline and demographic data
will be collected in standardized data collection form. Four ml of blood will be collected in EDTA coated vial and will
be used for DNA isolation. Genotyping will be done by using PCR-RFLP method. For the reconfirmation of RFLP results,
PCR product of each genotype in triplet for all the selected polymorphism will be sent for DNA sequencing. Data will
be analyzed using conditional logistic regression to determine odds ratio associated with the above genes.
Discussion: This protocol will assess the association of above mentioned gene polymorphisms with ischemic stroke in
North Indian Population. This study will also helpful to determine genetic component of stroke and whether variation
in genetic risk as per different subtypes of stroke.Background
Stroke has emerged as the second commonest cause of
mortality worldwide and is a major public health prob-
lem. Stroke has accounted for nearly 5.7 million deaths
worldwide in 2005 [1]. More than two-thirds of these
deaths occur in less developed countries [2]. The latest
available estimates from Indian Council of Medical
Research (ICMR) indicate that in 2004, 41% deaths and
72% disability adjusted life years (DALY) among non-* Correspondence: kp0704@gmail.com
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reproduction in any medium, provided the orcommunicable diseases were attributable to stroke [3].
Incidence of stroke is rapidly increasing in low and mid-
dle income countries. Incidence of stroke in South
Asian countries have increased by more than 100%
while this is deceased by 42% in developed European
countries in last four decade [4]. WHO estimates suggest
that by 2050, 80 percent of stroke cases in the world
would occur in low and middle income countries, mainly
India and China [5].
Stroke is a multi-factorial polygenic, complex disease
resulting from combination of vascular, environmental
and genetic factors [6]. There is large body of evidence,
suggesting a genetic component to stroke. Animal modelLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Kumar et al. BMC Neurology 2013, 13:136 Page 2 of 8
http://www.biomedcentral.com/1471-2377/13/136studies, twin and family-based association studies have
suggested the substantial genetic component of stroke
[7]. There is nearly several fold increase in the preva-
lence of stroke among the monozygotic compared with
the dizygotic twin pairs suggest that substantial contri-
bution of genetic in the risk of stroke [8].
Identification and management of new risk factors to
improve prevention remains an important strategy to re-
duce the human and economic burden of stroke [9].
Currently, there are only few drugs available for the
stroke treatment. Therefore, there is a clear need to
identify new drug targets. In view of ongoing advances
in personalized medicine on the basis of individual genetic
makeup, identification of SNPs for stroke will be helpful
for the development of specific drug target and patient
stratification for the treatment of stroke according to indi-
vidual genetic make-up. There is wide variation in study
results of various published candidate gene studies across
the different part of globe. Frequency of SNPs variant var-
ies across and within ethnic groups due to complex envir-
onment gene interaction. Factors responsible for varying
study results include different study design, variation in
sample size, and inadequate characterisation of pheno-
types and lack of case control matching. There is a clear
need to conduct more studies meeting the requirement of
standard guidelines such as STEREGA for genetics study.
We planned this study following this guideline. The study
will add to existing small body of evidence on genetics of
stroke in India. In this proposal, we plan to study some
important SNPs (Table 1) in North Indian stroke patients
by using candidate gene approach. We will also evaluate if
genetic risk varies across subtypes of ischemic stroke
according to TOAST classification [10]. We will also
examine whether single or in combination of genotypes
can predict the clinical outcome six months after stroke.
The objectives of the present study are (i) to determine
association of putative risk factor gene polymorphisms
(Table 1) and their haplotypes in ischemic stroke with dif-
ferent subtypes of ischemic stroke in North Indian popula-
tion, (ii) to investigate whether any association found
between ischemic stroke and the panel of testedTable 1 Location and characterization of polymorphisms to b
S. No. Gene Polymor
1. APOE Epsilon 2/3, epsilon
2. MTHFR C677
3. ENOS G894
4. Factor V Leiden 1691G>A (A
5. CYP4F2 1347
6. beta-fibrinogen (C148→
7. Phosphodiesterase 4D (PDE4D) SNPs 45 (rs12188950), SNP 8
(rs 2910polymorphisms is influenced by sex, age, or smoking status
and other environmental risk factors due to gene-
environment interactions, and (iii) to determine the fre-
quency distribution of the above mentioned polymorphisms
will be accordance with Hardy Weinberg equilibrium.
Justification for selection of genes
Methylenetetrahydrofolate reductase (MTHFR)
Several case control and prospective studies demon-
strated that moderate elevation of plasma homocysteine
(Hcy) is a potential risk factor for cardiovascular disease,
venous and arterial thrombosis including stroke [11].
Methylenetetrahydrofolate reductase (MTHFR) is an im-
portant enzyme in the metabolism of homocysteine. A
C677T mutation in this enzyme leads to a reduction in
enzyme activity and an elevation of plasma Hcy. Some
studies reported that C677T mutation is associated with
Ischemic stroke but others failed to find association. A
meta-analysis with 22 studies published in 2004 showed
odds ratio (OR) 1.24 (CI 1.08 to 1.42) having CC geno-
type and when compared with TT genotype. A meta-
analysis of 15 case control studies included 2034 cases
and 4485 controls showed significant associations be-
tween the MTHFR C677T genetic polymorphism and
risk of hemorrhagic stroke under dominant model (OR,
1.61; 95% CI, 1.3 to 1.9) and in recessive model (OR, 1.6,
95% CI, 1.4 to 2.0) [12]. A meta-analysis showed signifi-
cant association between elevated plasma homocysteine
levels and TT genotypes of MTHFR C677T polymorph-
ism in healthy South Asians [13].
Apolipoprotein E (APOE)
Apo-E protein contributes a major role in lipid trans-
port and metabolism and is also significantly expressed
in brain. Apo E is one of the commonly studied genes in
vascular and neurodegenerative diseases. Its protein
product are composed of glycoprotein with 3 common
isoforms, E2, E3, and E4, encoded by the respective al-
leles ɛ2, ɛ3, and ɛ4, giving rise to 6 genotypes. There is
substantial evidence of association of Apo ɛ4 allele with
elevated LDL cholesterol levels and thereby increasese studied
phism Role in mechanism of stroke
3/3, or epsilon 3/4 Arthrosclerosis
T Arthrosclerosis, venous thrombosis
T Arthrosclerosis
rg506Gln) Venous thromboembolism
G/A Vasoconstriction, increase in vascular tone
T) Carotid arthrosclerosis
3 (rs 966221) and SNP 87
829),
Arthrosclerosis
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that elevated level of Apo E in plasma is an important
risk factor for stroke. Apo E polymorphism can also
modify the risk of other modifiable risk factor e.g. the
effect of cigarette smoking on ischemic stroke may be
higher in young adults who carry the variant apo e 4 al-
lele [14]. A meta-analysis published in 2006 [15] which
included 4096 cases and 16117 controls suggested Apo
E contribute the risk of stroke with an OR, 1.11; 95% Cl,
I.01 to 1.22).Endothelial nitric oxide synthase (eNOS)
The eNOS gene is located on chromosome 7 (7q35-
q36) and consists of 26 exons. It codes for an enzyme
that generates Nitric Oxide (NO) in the vascular endo-
thelium. NO mediates the vasodialation in the endo-
thelium and it also inhibits the adhesion of platelets
and leukocytes and limits the oxidation of atherogenic
low-density lipoproteins in the vascular endothelium.
Impaired endothelium-dependent vasodilatation is a com-
mon feature of atherosclerotic vessels, which seems to be
partly due to the reduction in the activity of vascular
endothelial nitric oxide synthase. Impaired nitric oxide-
dependent vasomotor reactivity has been implicated in the
pathophysiology of stroke. Since it has an important
role in the physiology of the vasculature, genetic vari-
ation could alter the expression and activity of eNOS,
and therefore contribute to the development of stroke.
A meta-analysis [16] published in 2009 suggested, TT
genotype of G-894T polymorphism has no association
with ischemic stroke (OR, 1.14; 95% CI, 0.99 to 1.31). A
recent meta-analysis included 27 studies suggest the
positive association between eNOS gene 4b/a, T-786C,
G894T polymorphism and ischemic stroke [17].Factor V Leiden
The factor V gene is located on chromosome 1.q23,
spans more than 80 kb and contains 25 exons. In exon
10 where G nucleotide is replaced by A nucleotide re-
sults in an amino acid substitution of arginine at pos-
ition 506 by glutamine. This substitution blocks a major
cleavage site of activated protein C (APC), thereby
resulting in a decreased ability of APC to inactivate the
procoagulant factor Va which result in hypercoaguable
state that leads to an increased risk for venous thrombo-
embolism. A meta-analysis showed that Factor V Leiden
is associated with ischemic stroke in young adults,
particularly in patient populations where there is an
increased clinical suspicion of prothrombotic state. A
meta-analysis of 767 cases and 4020 controls observed
that Factor V Leiden 1691 G→A is associated with pa-
tients with adult venous thrombosis patients (OR 2.40;
95% CI, 1.75 to 3.3) [18].beta-fibrinogen (−148 C/T) gene polymorphism
Plasma fibrinogen is an important component of the co-
agulation cascade, as well as important determinant of
blood viscosity and blood flow. Increased level of fibrino-
gen may promote a prothrombotic or hypercoaguable
state and may explain the involvement in risk of stroke.
Fibrinogen is encoded by three separate genes located in a
50-Kb cluster on the long arm of chromosome number 4,
which encode α, β and γ chains. The rate limiting step in
fibrinogen formation is the synthesis of the β-polypeptide
chain regulated by a β-fibrinogen promoter. C148T
polymorphism of beta is located close to an interleukin-
6 responsive element and may affect fibrinogen gene ex-
pression, mainly in response to acute phase reaction.
Studies support C148T polymorphism is associated with
increased plasma fibrinogen level in both men and
women in general population. There are numerous
studies describing an association between plasma fi-
brinogen levels and coronary heart disease and stroke
and carotid atherosclerosis. Fibrinogen concentration is
controlled by genetic and environmental factors, including
smoking, obesity, use of contraceptives, trauma, and lack
of exercise, which have been reported to elevate fibrinogen
concentrations. Fibrinogen level also increases with age
and in the presence of diabetes mellitus, hypertension, or
lipid abnormalities. A meta-analysis of eleven studies in
Chinese population included 1223 cases and 1433 controls
showed the pooled OR of susceptibility to cerebral infarc-
tion for -148T allele carriers was 1.32; 95% CI, 1.12 to 1.55
when compared to wild homozygous [19].Phosphodiesterase 4D (PDE4D)
PDE4D gene is located on short arm of chromosome
number 5q12 and consists of 24 exons. The gene ex-
presses nine different functional protein isoforms through
alternative splicing or the use of differential promoters.
The different PDE4D variants are expressed in various
tissues including brain, lungs, kidneys, monocytes, B and
T lymphocytes and vascular smooth muscles [20]. PDE4D
is the family of enzyme which breaks phosphodiester bond
of cAMP degrades them and maintains the appropriate
level and duration of action of cAMP within the cell. Cyc-
lic AMP is secondary signaling molecule which involves
provoking genes to produce inflammatory mediators by
several types of inflammatory cells and arthrosclerosis.
PDE4D degrade cAMP, therefore responsible for subsiding
inflammatory process by stop massaging through cAMP
to genes that produce inflammatory proteins. Polymorph-
ism in this gene may affect catalytic efficiency of PDE4D.
In 2002, the deCODE group published the results of a
genome wide screen for stroke susceptibility genes in
Iceland [21]. Among 260 phosphodiesterase 4D (PDE4D)
single-nucleotide polymorphisms (SNPs) examined, six
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for multiple comparisons.
Cytochrome P450 4F2 (CYP4F2)
The cytochrome P450 4F2 (CYP4F2) gene, prominently
expressed in human kidney and liver, encodes a ω-hydroxylase
that catalyzes the metabolism of arachidonic acid, leukotri-
ene B4, and tocopherol. The 20-hydroxyeicosatetraenoic
acid (20-HETE), derived from arachidonic acid by CYP4F2
in the kidney, acts as a natriuretic and vasoactive eicosanoid
and plays an important role in the control of renal function
and systemic BP. Considerable evidence showed that al-
tered renal 20-HETE content and CYP genes may play
an important role in hypertension and ischemic stroke.
One study reported from south India found association
of 1347 G/A polymorphism (rs2108622) with stroke [22].
Methods/Design
Ethical considerations
Study Protocol has been approved from Institutional Ethics
Committee (Ref No: IEC/NP-122/2012 & RP-14/2012).
Design of study
Case control study design.
Patients and methods
Patients will be eligible if they meet all the inclusion
criteria and none of the exclusion criteria.
Selection of cases and controls
Inclusion and exclusion criteria for cases
Inclusion criteria for cases
a) Diagnosis of stroke as defined by World Health
Organization, b). NCCT-Head consistent with ischemic
stroke, c). Stroke onset within three years before the
recruitment, d). Age 18–85 years (both sexes),
e). Willingness to provide written informed consent by
self or legal representative, f ). Should be resident of
North India (residing for last one year or longer),
g). Be ’North Indian’. A North Indian defined in
consultation with Department of Paediatric (Genetics)
AIIMS and Genetics Department of the Institute of
Genomics and Integrative Biology (IGIB) as having all of
the following:(i) The subject’s birth place should be in North India,
(ii) Their ancestor (2 generation) should be North
Indian, (iii) Subjects must know any North Indian
language which include any language spoken in North
India.For this study, North India included the states of
Himachal Pradesh, Bihar, Delhi, Punjab, Uttar Pradesh,Madhya Pradesh, Uttrakhand, Jharkhand, Rajasthan,
Jammu and Kashmir and Haryana.
Exclusion criteria for cases
a). Stroke associated with pregnancy, b). Stroke associated
with surgery, c). Unwillingness to provide written
informed consent (by self or legal representative).
Inclusion and exclusion criteria for controls
Inclusion criteria for controls
a). Age (−5 to + 5) and sex matched, b). Controls have
not had prior stroke by questionnaire for Stroke-free
Status (QVSS) [23], c). Spouse or friends but not a
relative (by blood), d). Age 18–85 years (both sexes),
e). Should be Resident of North India (residing for
last one year or longer), f ). Willingness to provide
written informed consent by self or legal
representative, g). No evidence of any serious brain
disorders, h). Be ’North Indian’. (North Indian criteria
is same as above).
Exclusion criteria for controls
a). Unwillingness to provide written informed consent
(by self or legal representative), b). Pregnancy, c). Subjects
with any serious brain disorder.
Definition of variables
Definitions of variables were modified from the study
[24] and are as follows: Hypertension: Subjects will be
considered to have hypertension if they either have the
diagnosis of hypertension or treated for hypertension
before the stroke or reference date, In addition, if a
control will have no recorded blood pressure before the
reference date but diastolic pressure of 95 mm Hg or
more or a systolic pressure of 160 mm Hg or more on two
or more occasions during the study evaluation, he or she
will be considered to have hypertension. Diabetes: if a
subject will have the diagnosis documented by a physician
on the medical record or if fasting blood sugar level will
be >126 mg/dl, Dyslipidemia: if they either will have the
diagnosis of dyslipidemia or treated for dyslipidemia. An-
gina pectoris: chest discomfort or pain that described as
heavy, tight, constricting, crushing, pressing, or squeezing.
Smoker: Person will be defined as regular smoker if a per-
son smoking ≥1 cigarettes daily, Biris, Cigar for proceed-
ing>3 months. Body Mass Index (BMI): BMI will be
calculated by weight in kilograms divided by the square of
height in meters. Family history of Stroke: A positive
family history of stroke will be considered if a subject’s
first-degree relative (parent or sibling) had a stroke.
Myocardial Infarction: The diagnosis will be based on
Kumar et al. BMC Neurology 2013, 13:136 Page 5 of 8
http://www.biomedcentral.com/1471-2377/13/136clinical history of acute myocardial infarction; Migraine:
subject will be considered to have a history of migraine if
patients have a prescription for specific antimigraine ther-
apy or diagnosis of migraine and a prescription for a
potential antimigraine medication or analgesics in the
absence of any other explanatory diagnosis within 1 years
before the index date; Transient Ischemic Attack: TIA
will be defined as subjects with focal neurologic symptoms
relating to focal cerebral, brain stem, or retinal ischemia
with abrupt onset and complete resolution within 24 hours.
Economic status: the economic status of the subjects will
be assessed based on the ownership of different commod-
ities in house hold, mainly two wheeler, refrigerator, com-
puter or car. The economic status will be classified into
two classes: Low – not possessing any of the four, High:
possessing either two- wheeler or refrigerator or computer
or car. Physical activity will be determined on the basis
of job profile of the subjects in which Sedentary (mostly
sitting e.g. shopkeeper, clerk; Moderate physical activity
(involves walking e.g. salesman, nurses, house work
etc.); Heavy physical work (carrying, lifting e.g. labourer,
coolie).
Matching criteria for control to case
Matching is required for case control study for the elim-
ination of bias in comparison between cases and con-
trols. It assures that no large imbalance between cases
and controls occurs. Controls will be matched with gen-
der and age (± 5 years of cases) in 1:1 ratio. As Spouses
would have similar environmental exposure as cases
spouse can be used as control for case control stroke
genetics study [25]. We will use spouses of cases as a
match for other cases for age and sex matching. If there
would be any lag and unavailability of spouse we will re-
cruit age and sex match control from relatives/patients
attending neurology department for treatment other
than stroke and fulfilling the inclusion criteria for re-
cruitment of controls.
Stroke classification
We will use TOAST classification for the determination
of stroke subtypes [10]. In TOAST classification stroke
has five subtypes (i) Large vessel stroke (ii) Small vessel
stroke (iii) Cardioembolic stroke (iv) Other determined
aetiology (v) Undetermined aetiology.
Sample size
Sample size calculation for all gene polymorphism was
based on the parameters of our meta-analysis of associ-
ation of MTHFR polymorphism with stroke. In this
meta-analysis result prevalence for TT variant genotype
were 0.17 and 0.13 in cases and control respectively, Odds
ratio for this polymorphism was 1.31 Assuming 80%
power and 5% alpha, with one control per case, weobtained estimated minimum sample size 578 cases and
578 controls. 600 cases and 600 controls will be included
in this study to compensate for any loss of sample.
Blood sample collection, processing, storage and
genotyping
Four ml of blood sample will be collected in EDTA
coated vial from all consenting participants in single-
time venipuncture from antecubital vein. Samples will
be used for Genomic DNA isolation from white blood
cells by using phenol chloroform isolation method and
extracted genomic DNA will be dissolved in 200-600 ml
TE buffer depending upon the concentration of DNA
and will be stored at -20°C. DNA will be isolated in
weekly basis for isolation of good quality of DNA. Its
quality will be checked first in 0.8% agarose gels. Quality
of DNA in per μl will be checked in Nanodrop spectro-
photometer. The purity of the DNA sample will be
ascertained by calculating a 260/280 ratio. The ratio
between 1.5-1.8 will be acceptable for PCR amplification.
Genotyping will be done by the PCR – RFLP method. The
PCR-RFLP results will be confirmed by direct sequencing
of three samples of each genotype of all the chosen
polymorphisms.
Data collection and data analysis
Data will be recorded in standardized data collection
forms. The data will be managed and analyzed using stat-
istical software SPSS version 17. T-test will be used for
continuous variables. Chi Square tests and logistic regres-
sion techniques will be used when outcome variable are
categorical (Present/Absent). Association between each
risk factor of interest and stroke will be performed using a
conditional logistic regression approach. Odds ratio (ORs)
and corresponding confidence intervals will be calculated
for each polymorphism. A multivariable conditional logis-
tic regression analysis will be performed for adjustment of
other covariates. The other associated risk factors will be
treated as covariates in examining the associations with
stroke. Significance in the final model will be defined as
P<0.05. Phenotype-genotype and genotype-environment
interaction will be analyzed using routine statistical
methods. Haplotypes will be constructed from selected
SNPs and its association with stroke will be estimated
using regression techniques
Outcome measure
The primary outcome of the present study is to deter-
mine whether singly or in combination of any of selected
polymorphisms are associated with stroke or its sub-
types. Cases will be compared with controls to frequency
and distribution of susceptible allele. Other outcome
measure includes association of gene polymorphisms
with different environmental exposures such as
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from association of genetic polymorphism with outcome
of stroke is lacking. Determining the relationship of gen-
etic variations with the stroke outcome will improve our
understanding that how variations in the genes influence
the stroke outcome. In present study we will assess the
outcome of recruited patients at six months by tele-
phone to assess the status of patients. One research
worker will assess the Barthel Index and modified Rank-
ing scale after the six months of stroke. Chronic stroke
patient who will come after the six months of onset of
stroke their six months Barthel index and modified
Ranking scale will be assessed retrospectively.
Discussion
Several candidate genes association studies with Apolioprotein
E (APOE), MTHFR, ENOS, Factor V Leiden, cytochrome
P450 4F2 (CYP4F2), beta-fibrinogen Gene and PDE4D
gene polymorphism in stroke resulted in conflicting re-
sults. This study will have taken appropriate measure to
deal with this issue.
Strengths of the study
There are inconsistent results on candidate gene asso-
ciation studies in stroke and they have been criticized
for non-replicability [26]. The possible reasons for the
wide variations includes (i) variation in the method-
ology, (ii) lack of proper selection of the cases and control,
(iii) lack of proper definitions of variables for phenotypic
and genotypic data collection, (iv) insufficient sample size,
(v) inappropriate control, who are often not screened, in-
correctly matched with patients, and recruited in absence
of strict criteria mainly from hospital staffs and known to
researchers. Present study has taken measures to limit the
above shortcomings.
Correct definitions of cases and of all the variables are
crucial for a case control study. There is 39 fold increase
in sample size for genetic association studies when the
misclassification rate is 5% and disease prevalence is 1%
[27]. There are two levels at which misclassification can
occur: First, there could be misclassification of cases and
controls. Second, there could be misclassification among
cases (or controls) on whether they have the variable
(risk factors) or not. A clear definition of cases and oper-
ational definition of variables helps to minimize the
misclassifications. Misclassifications of the second kind
may be differential or non-differential. While differential
misclassification introduces systematic error in the meas-
urement, the non-differential misclassifications introduce
random error (Schlesselman, 1982) [28]. Many of reported
candidate gene studies did not provide definition of cases
and controls. Definitions of variables vary across the dif-
ferent scenario and even in the same disease at different
time periods. For instance, in the acute phase of stroke,there is transient reactive hypertension. Therefore, the
usual definition of hypertension systolic blood pressure
140 or above/ or diastolic blood pressure 90 or above may
misclassify patients. Therefore, it is essential to provide
operational definitions of variables in case control study.
This study attempted to provide a clear definitions of cases
and controls as well as clear operational definitions of
variables.Selection of controls
Selection of controls for the genetic case control study is
the most difficult part of study. Schleselman point out,
(Schlesselman, 1982) “the control series is intended to
provide an estimate of the exposure rate that would be
expected to occur in the cases if there were no association
between the study disease and exposure”. In present study,
we will use age and sex matched controls. Controls will be
selected from hospital mainly from spouses which serve as
better controls as they would have similar environmental
exposure [25]. Spouses of cases will be matched to other
cases with same sex. This will allow us to reduce the bias
due to effect of environment exposures between cases and
controls. Any lag in case of unavailability of spouse will be
fulfilled by age- and- sex match unrelated patients/relative
(unrelated by blood) who will be seeking medical care
from Neurology Outpatient Department for conditions
other than stroke and fulfilling inclusion and exclusion cri-
teria of the present study. This will allow us to select the
controls to approximate distribution of exposure among
them to that in the population from which cases arise.
We attempted to properly define the geographical area
from cases and controls will be recruited. This will allow
us to maximize genetic homogeneity in the study
population.Bias in genotyping
Genotyping error may lead to misclassification of 30% of
samples [27]. It is essential to reduce the genotyping
error for genetic association studies to reduce the false
positive or negative association of allele to the diseases.
There are various reasons for genotyping error such as
failure to identify the triallelic SNP, partial digestion of
PCR product in PCR-RFLP method, lack of blinding to
personnel undertaking genotyping for case control status
of samples. In our study research personnel, who will be
responsible for genotyping, will be blinded to case
control status of the sample. In several circumstances
there is incomplete digestion of PCR product which may
lead to bias in the genotyping. To deal with this issue in
our study, RFLP image will be read by the two investiga-
tors separately. A third person will resolve the issues
wherever discrepancies occur.
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Original proportion of genotypes in the population
remains constant from one generation to next in the
absence of evolutionary forces. Many factors lead to de-
viation from the hardy Weinberg equilibrium like popu-
lation stratification and random chance. It is essential to
check in the genetics study whether distribution of ob-
served alleles and genotypes are in accordance with
Hardy Weinberg equilibrium in both cases and controls.
Minor to modest deviation may provide the false posi-
tive association of variant with the disease. In several
published candidate gene studies have not presented
data whether their genotypic frequencies followed the
Hardy-Weinberg equilibrium. In our study we will
check whether the frequency distribution of genotypes
following Hardy-Weinberg equilibrium or not. If there
would be deviation from Hardy-Weinberg equilibrium,
essential statistical measure will be adapted to deal with
this issue.Outcome data
Recovery of stroke greatly varies from individual to indi-
vidual after the onset of stroke depends upon clinical,
radiological parameter and individual genetic composition.
Association data of genotype with the better recover or
poor recovery after the onset of stroke are lacking in the
literature. In our present study we will examine associ-
ation of specific genotype with six month stroke outcome.
We have taken appropriate measure to improve the
quality of study. This study will provide quality data on
association of above polymorphisms, in accordance with
STEREGA guidelines. This study will improve our un-
derstanding of its risk factors and will facilitate identifi-
cation of individuals at increased risk of disease. A clear
and comprehensive understanding of genetic risk may
promote advances in gene therapy and in the develop-
ment of novel pharmaceutical agents for the treatment
for stroke. Identification of genetic risk factors will be
helpful for the better prevention of stroke.
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